Rules-Based Medicine

(+01) 512 835 8026

Email us

Type your search term and press "enter."



Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL)

Ultrasensitive Immunoassay


Rules-Based Medicine’s (RBM) internally developed and manufactured ultrasensitive immunoassay to Receptor Activator of Nuclear Factor Kappa-Β ligand (RANKL) based on the Simoa® bead technology can accurately quantitate sub-pg/mL levels of RANKL in human serum and plasma. Such sensitive RANKL detection may be useful for clinical studies related to bone remodeling, tumorigenesis, and autoimmune diseases.

RANKL is a type II membrane protein that bears a close homology to tumor necrosis superfamily members: TRAIL, FasL, and TNF-a. It is produced by a variety of cells and tissues, but highly in T lymphocytes, osteoblasts, osteocytes, lungs, thymus, and lymph nodes. Several factors regulate RANKL expression, including glucocorticoids, Vitamin D3, IL-1, TNF-a, TGF-b, Wnt ligands, and LPS. RANKL has both a membrane-bound form and a soluble form via cleavage by TNF-a convertase. The primary function of RANKL is n bone remodeling and metabolism and in the regulation of T cell dependent immune responses. The receptor for RANKL is RANK, and osteoprotegerin is a decoy receptor that triggers different signaling pathways.

The RANKL/RANK/OPG pathway contributes to breast cancer initiation and progression, and RANKL expression has been correlated with other cancers, including metastatic prostate carcinoma and multiple myeloma. In autoimmune diseases, such as rheumatoid arthritis, RANKL has been linked to the progression of bone erosion and destruction. RBM’s ultrasensitive assay for the detection of RANKL could be a valuable tool for clinical studies investigating RANKL correlated pathologies.


Swiss-Prot Accession Number: O14788

Alternate names for this biomarker include:

Tumor necrosis factor ligand superfamily member 11, Osteoclast differential factor, ODF, Osteoprotegerin ligand, OPGL, TNF-related activation-induced cytokine, TRANCE, CD254

Simoa™ Services
Biomarker LLOQ*
(Serum and Plasma)
(Undiluted Samples)
Volume Required
Serum or plasma Other fluids**
Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) 0.58 pg/mL 0.145 pg/mL 100 µL 150 µL

* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.

** Cerebrospinal fluid, urine, tissue culture supernatants,  bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.

All assay services are performed in our CLIA-certified laboratory.
Intended for Research Use Only.